Xeris Biopharma Holdings, Inc.
XERS
$8.48
-$0.05-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 28.74% | 38.27% | 42.78% | 37.06% | 48.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.74% | 38.27% | 42.78% | 37.06% | 48.84% |
| Cost of Revenue | 5.16% | 21.15% | 15.50% | -19.11% | 52.73% |
| Gross Profit | 33.45% | 41.18% | 47.88% | 55.83% | 48.08% |
| SG&A Expenses | 37.49% | 20.73% | 18.34% | 3.31% | 11.00% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.04% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.63% | 18.99% | 18.17% | 0.73% | 19.21% |
| Operating Income | 15.42% | 356.18% | 898.99% | 152.21% | 154.75% |
| Income Before Tax | -1,513.12% | 124.23% | 316.72% | 103.26% | 86.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,513.12% | 124.23% | 316.72% | 103.95% | 87.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,513.12% | 124.23% | 316.72% | 103.95% | 87.15% |
| EBIT | 15.42% | 356.18% | 898.99% | 152.21% | 154.75% |
| EBITDA | 9.16% | 16,966.15% | 321.41% | 199.04% | 244.69% |
| EPS Basic | -1,387.60% | 121.65% | 294.75% | 103.60% | 88.03% |
| Normalized Basic EPS | 84.21% | 121.69% | 294.86% | 102.94% | 87.86% |
| EPS Diluted | -1,387.60% | 116.53% | 288.63% | 103.18% | 88.03% |
| Normalized Diluted EPS | 84.21% | 120.90% | 279.91% | 102.69% | 87.86% |
| Average Basic Shares Outstanding | 8.38% | 11.86% | 11.31% | 9.84% | 7.49% |
| Average Diluted Shares Outstanding | 8.38% | 16.52% | 20.78% | 19.21% | 7.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |